Status:
UNKNOWN
Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric Cancer
Lead Sponsor:
Anhui Provincial Hospital
Conditions:
Two Different Treatment Methods
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The investigators hope that after this research, two different treatment methods' curative effects for advanced gastric cancer can be assessed. One is continuous use of apatinib, the other is 5 days' ...
Eligibility Criteria
Inclusion
- Male and female patients,age≥18years
- Confirmed by Pathology or histology of Gastric cancer
- Patients who failed first-line chemotherapy
- The ECOG physical status score:0 to 2
- Expected survival ≥3months
- Patients should be voluntary to the trail and provide with signed informed consent.
- The researchers believe patients can benefit from the study.
Exclusion
- Pregnant or lactating women
- Patients with a knowm history of allergic reactions and/ou hypersensitivity attributed to apatinib or its accessories
- Patients with apatinib contraindications
- Patients of doctors considered unsuitable for the trail
Key Trial Info
Start Date :
October 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2019
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03334591
Start Date
October 1 2017
End Date
December 1 2019
Last Update
November 14 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Anhui Provincial Cancer Hospital
Hefei, Anhui, China, 230000